Table 2. Antihypertensive therapy and placental concentrations of angiogenic factors.

	PE			GH			Controls
	Anti-hypertensive (n = 7)	No anti-hypertensive (n = 7)	P value	Anti-hypertensive (n = 5)	No anti-hypertensive (n = 5)	P value
sFlt-1 (ng/ml)	17.7 (3)*	33.9 (5)*	0.01	3.1 (0.4)	5.3 (0.8)	0.06	5.2 (1.2)
PlGF (pg/ml)	8.4 (1.8)*	7.7 (2)*	0.56	20.7 (3)	15.9 (4)	0.18	23.9 (5)
sEng (ng/ml)	13.1 (1.6)*	19.6 (1.7)*	0.02	3.8 (0.4)	4.3 (0.3)	0.35	3.5 (0.2)
VEGF (pg/ml)	107.5 (30)*	247 (82)*	0.09	108 (39)*	166 (32)*	0.1	10.4 (1.2)

Placental concentrations of sFlt-1, PlGF, sEng and VEGF (expressed per mg protein) in normotensive controls, pre-eclampsia (PE) and gestational hypertension (GH), grouped according to whether they received antihypertensive therapy or not. The mean gestational ages for the three groups were (mean±SD): controls 242±16; pre-eclampsia 238±13; gestational hypertension 243±20. The P values represent the statistical difference between the groups with hypertension who received antihypertensive therapy or not.

PE = pre-eclampsia.

GH = gestational hypertension.

Data presented as mean (standard error of the mean), and analyzed by independent t test.

^* P<0.05 compared with normotensive control group.